Introduction: breast cancer is among the most common cancers among women in most of Africa. However, features of histologically confirmed
Introduction
Breast cancer is the most common cancer affecting women in Africa (100per 100,000), and is the second leading cause of cancer deaths (49 per 100,000) [1] . Western African countries have an average estimated breast cancer incidence of 20-25 per 100,000 women, second only to cervical cancer [2] . Age-standardized incidence rates are comparatively lower in Senegal (22.4 per 100,000) than other regional rates (i.e. Nigeria 50.4 per 100,000), although limited data and cancer registries may alter the estimates of population incidence.
Despite the lower overall incidence of breast cancer, survival rates are significantly lower in Africa when compared to North America; while breast cancer survival rates approach 80% in North America, survival rates are below 40% in low income countries [3] . Socioeconomic factors that limit access to health care contribute to this disparity. Genetic factors and breast cancer phenotypes may also influence the aggressive breast cancer presentations and outcomes in African women [4] . Prior studies have found that women in some African countries present later in the disease course, are affected at younger ages, and have more aggressive breast cancer phenotypes including 61% triple negative phenotypes from a study in Ghana [5] .
Other studies from the Ivory Coast, Nigeria, and Uganda found lower rates of triple negative breast cancers (30-35%) suggesting genetic and demo-graphic variability [6] [7] [8] [9] . In this study, we further characterize the clinic-pathologic characteristics of breast cancers in women presenting with masses in Senegal, West Africa. Tumor Institute with masses clinically diagnosed as breast cancer and who had not undergone previous biopsy, surgery, or therapy, were enrolled in the study. Women with a clinical diagnosis of breast cancer were enrolled for pathological evaluation of the suspected breast cancer. After providing informed consent, the study participants were interviewed to elicit information regarding demographic characteristics, gynecologic history, use of cigarettes and alcohol, family history of cancer, and medical history. All women underwent a physical examination and medical history, and in a subset of women, blood was collected for methylation studies as previously described and reported separately [10] . Size of the presenting breast mass was estimated by clinical examination. Information regarding study patient demographic characteristics was collected on site in study questionnaires, entered into an access database, and later linked to pathologic characteristics, which were ascertained on core biopsy samples subsequently reviewed at the University of Washington, in Seattle. Data analyses were performed using STATA version 14.1.414.
Methods
Venn diagrams were created using BioVenn [11] . Initial diagnoses were made by local study pathologists and reviewed centrally by a single pathologist (author KHA) for further characterization of histologic subtype, grade (using the Nottingham scoring system). Needle core biopsies with available additional tissue were stained by immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67 and were included in this study [12] . Tissue sections were deparaffinized followed by blockade of endogeneous peroxidases and antigen retrieval using Antigen Unmasking Solution (Vector). ER clone 1D5 using a dilution of 1:1000, following a 15-minute pretreatment in citrate buffer, pH = 6.0 and PR (BioGenex) clone PR88 using a dilution of 1:100 following an 18-minute pretreatment in citrate buffer pH = 6.0. The slides were then counterstained in hematoxylin, dehydrated, and mounted.
Positive and negative external controls were performed. HER2 was defined as positive if IHC was 3+ (strong circumferential membranous staining), with adequate internal and external controls. ER and PR scoring was performed using the Allred scoring system with an Allred score ≥ 3 considered a positive result [13] . Anti-HER2 polyclonal antibody (catalog No. A0485, diluted 1:200; DAKO, Carpinteria, CA) staining was performed and scored using a method previously described [14] . Fluorescence in situ hybridization (FISH) for HER2 gene amplification status was performed on HER2 IHC equivocal cases. HER2 FISH was performed manually according to the vendor's protocol using the US Food and Drug Administration-approved Vysis PathVysion (Abbott-Vysis, Des Plaines, IL) using methods previously described [15] . A ratio of > 2.0 was considered as a positive result.
Results
Of the 522 women enrolled, the presence of invasive cancer was confirmed by cytology and/or core biopsy histology in 397 (76.1%) cases. Non-invasive cancer diagnoses included benign abscesses and lesions, fibroadenomas, phyllodes tumors, papillomas, and ductal carcinoma in situ. Eighteen subjects had insufficient samples for diagnosis. Of confirmed 397 invasive cancer cases, 197 were subsequently stained by IHC for ER, PR and HER2 performed on needle core biopsy specimens. Mean age at presentation was 47.0 years, and 54.4% were premenopausal (Table 1 ). Mean gravidity was high (5.7 pregnancies/women), and study subjects rarely had a reported history of hormonal contraception (10%), alcohol use Most strikingly, almost half of Senegalese breast cancers were triple negative, a much higher proportion than observed studies in East and North African countries, such as Uganda, where the rates of triple negative breast cancers are comparatively lower (34%) and more comparable to the United States and Europe [6, 8, 9, 20, 22] . Our data is more similar to other West African studies. For example, a study from Ghana found that 61% of breast cancers were triple negative [6] . This high rate of triple negative breast cancers in West Africa, the founder population of most African Americans, is in keeping with the clinico-pathologic features of breast cancers among non-Hispanic black women in the United States (younger age at presentation and higher frequency of triple negative cancers than the general population) [19] . These findings suggest a genetic and/or epigenetic influence, which has recently been discovered with data from the Cancer Genome Atlas. The CGA analysis found higher frequencies of estrogen receptor-negative breast cancer risk alleles in blacks than whites in the United States, providing further molecular basis of ER-negative phenotypes [23] . Additional studies exploring the genetic and epigenetic basis of these aggressive phenotypes are warranted. HER2+ breast cancers represented 14.7% of the breast cancers in our study, and were more commonly stage IV at diagnosis. This aggressive behavior is in keeping with the known aggressive clinical course in the era before available targeted therapy [24] . Given the high percentage of late stage diagnoses in our Senegalese cohort, we might have expected a much higher HER2+ percentage than 14.7%. This inconsistency raises the possibility of additional genetic and/or epigenetic influences specific to the Senegelese population.
While predisposing genetic factors seem to explain some of the differences, geneenvironment interactions are also implicated in the development of aggressive breast cancer phenotypes [25] .
Specifically, transcriptional silencing of tumor suppressor genes via methylation of CpG islands in promoter regions is thought to be an early step in carcinogenesis, and is largely influenced by environmental exposures such as biopsychosocial stressors [25] . Our previously published methylation data performed in this same cohort of women analyzed 32 genes known to be involved in hormone signaling, cellular proliferation, and DNA repair in breast carcinoma [10] . Five of these genes were found to be significantly methylated in breast cancers from our cohort in Senegal (APC, RASSF1, GASTP1, SCGB3a1, and HS3ST2). Hypermethylation was found more often in ER positive/PR positive and HER2 positive cancer whereas hypomethylation was more common in triple negative cancers, which is similar to other such methylation studies [10] . These epigenetic changes point to a complex interaction of genes and environment in the development of the aggressive phenotypes of cancers found in our study.
Conclusion
Our study contributes to the knowledge of the frequency of breast cancers with histologic confirmation. We found that breast cancers from Senegal tend to have aggressive clinico-pathologic features.
While it is still unclear what the relative contributions of populationspecific differences account for the distinctive breast cancer phenotypes in Senegal (such as mean age at presentation, screening programs and genetic/regional risk factors), a better understanding of the frequencies of these breast cancers phenotypes will help guide diagnosis and treatment. 
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